Sitemap xml

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.

Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group. . Bryant A, et al. Am J Ther. 2021 Aug 27;28(5):e573-e576. doi: 10.1097/MJT.0000000000001442. Am J Ther. 2021. PMID: 34469921 . Dia A, et al. Cell Host Microbe. 2021 Sep 1:S1931-3128(21)00385-1. doi: 10.1016/j.chom.2021.08.009. Online ahead of print. Cell Host Microbe. 2021. PMID: 34492224 . SenGupta T, et al. Cell Rep. 2021 Sep 7;36(10):109668. doi: 10.1016/j.celrep.2021.109668. Cell Rep. 2021. PMID: 34496255 .

Page

News

Page

News

Gluten intolerance a significant risk factor
Infectious disease of the uterus
Absence of an individual specific disease

Page

News

Welcome to HealthyDogPetCo Blog

Sitemap xml